Method for Treating Hyperuricemia in Patients with Gout Using Halofenate or Halofenic Acid and an Anti-Inflammatory Agent
AssigneeMetabolex, Inc.
InventorsGopal Chandra Saha, Brian Edward Lavan, Brian K. Roberts, Charles A. McWherter
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a urate-lowering agent and an anti-inflammatory agent. In some aspects the urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second agent is an anti-inflammatory agent, or a pharmaceutically acceptable salt thereof.
Claims23
A pharmaceutical composition comprising a first therapeutic agent and a second therapeutic agent,
- wherein the first therapeutic agent is a urate-lowering agent, and
- the second therapeutic agent is an anti-inflammatory agent.
A method for treating a gout flare experienced by a subject comprising concomitantly or sequentially administering to the subject a first therapeutic agent and a second therapeutic agent,
- wherein:
- the first therapeutic agent is selected from the group consisting of (−)-halofenate, (−)-halofenic acid, and pharmaceutically acceptable salts thereof;
- and
- the second therapeutic agent is colchicine.
A method for reducing the number, duration, frequency or intensity of gout flares experienced by a subject comprising concomitantly or sequentially administering to the subject a first therapeutic agent and a second therapeutic agent, wherein:
- the first therapeutic agent is selected from the group consisting of (−)-halofenate, (−)-halofenic acid, and pharmaceutically acceptable salts thereof;
- and
- the second therapeutic agent is colchicine.
A method for the treatment of hyperuricemia in a subject with gout comprising concomitantly or sequentially administering to the subject a first therapeutic agent and a second therapeutic agent, wherein:
- the first therapeutic agent is selected from the group consisting of (−)-halofenate, (−)-halofenic acid, and pharmaceutically acceptable salts thereof;
- and
- the second therapeutic agent is colchicine.
Dependencies are inferred from the claim text.